DNA Sequencing Market Summary
As per MRFR Analysis, the DNA Sequencing Market was valued at USD 13.46 billion in 2023 and is projected to reach USD 46.85 billion by 2032, growing at a CAGR of 12.97% from 2024 to 2032. Key drivers include advancements in sequencing technology, increased applications in personalized medicine, and rising demand for genomic research. The market is segmented into consumables, instruments, and services, with consumables holding the largest share. Applications span diagnostics, oncology, and forensics, with significant growth expected in personalized medicine. North America leads the market, followed by Europe and Asia-Pacific, with notable investments in R&D and technological advancements fueling growth.
Key Market Trends & Highlights
The DNA Sequencing Market is witnessing significant growth driven by technological advancements and increased applications.
- Market Size in 2023: USD 13.46 billion; projected to reach USD 46.85 billion by 2032.
- CAGR of 12.97% during the forecast period (2024-2032).
- North America accounted for USD 1.05 billion in 2022, leading the market share.
- Biomarkers & cancer applications hold a considerable market share, driven by rising cancer prevalence.
Market Size & Forecast
2023 Market Size: USD 13.46 billion
2024 Market Size: USD 15.63 billion
2032 Market Size: USD 46.85 billion
CAGR: 12.97% (2024-2032)
Largest Regional Market: North America.
Major Players
Key players include Illumina, Inc., Roche, Thermo Fisher Scientific, QIAGEN, and Pacific Biosciences.
DNA Sequencing Market Trends
- Increased technological advancement to boost the market growth
DNA sequencing technology can sequence multiple DNA strands through massive parallelization. Such sequencing includes Sanger sequencing and non-Sanger sequencing. Compared with microarrays and other genomic analysis methods, DNA sequencing has the advantages of low cost, high accuracy, high speed, and precise results, even with small sample input volumes. DNA sequencing is used to perform a variety of applications, such as biomarker discovery, oncology research, personalized medicine, forensics, and more. It simplifies nucleotide analysis and is a broad alternative to traditional genomics tools, notably microarrays, genotyping, and more. The demand for DNA sequencing has increased significantly owing to the proliferation of sequencing applications and the increase in technological advancements in DNA sequencing. Moreover, the surge in genome mapping initiatives and increasing investment in research and development across the globe drive market growth.
DNA sequencing has brought about a paradigm shift in proteomics and genomics research. It is a highly accurate and high-throughput technology used in various applications such as de novo assembly, WGS, and DNA resequencing. Therefore, the technology is quickly adopted by several academic research institutions for research. Illumina installed the NovaSeq 6000 Sequencing System at the Whitehead Biomedical Research Institute in Massachusetts, USA, in June 2020.
The market of DNA sequencing is driven by efforts by the Centers for Medicare & Medicaid Services (CMS), the Society for Molecular Pathology, and commercial payers such as Blue Cross Blue Shield and Aetna to facilitate the clinical use of sequencing technology. For example, in January 2020, China Medical System expanded the coverage of NGS-based diagnostic tests for ovarian and breast cancer patients, providing patients with more opportunities for personalized cancer care. Therefore, the market CAGR of DNA Sequencing has been increasing globally in recent years. These are essential factors driving the DNA Sequencing market revenue growth.
The sequencing of DNA is a method that uses extensive parallelization to sequence many DNA strands. Both Sanger's technique and non-Sanger methods of sequencing are used in this sequencing. The development of pharmacological treatments for cancer is accelerated by individualized targeted sequencing of tumors, which also discovers cancer targets or pathways. Introducing large-scale initiatives utilizing NGS techniques produces a fresh fundamental understanding of oncology precision therapy. Compared to microarray and other genetic analysis methods, DNA sequencing offers advantages such as excellent accuracy & speed, cheap cost, and accurate results even with limited sample input. Biomarker identification, forensic analysis, oncology research, and individualized healthcare are among the uses for DNA sequencing.
It has greatly outperformed more traditional genomics methods, including genotyping, microarray, and others, and has sped up the study of nucleotides. DNA sequencing, a highly accurate and high-throughput technology utilized for various applications, including WGS, de novo assembly, and DNA resequencing, has caused an upheaval in proteomic and genomic studies. As a result, several academic research institutions can utilize this technology for research investigations. Consumer call for DNA sequencing has significantly increased due to the surge in sequencing applications and growth in DNA sequencing technology. Additionally, a boost in worldwide genome mapping efforts and R&D spending drive the market's expansion.
Technology advancements in DNA sequencing, increased clinical diagnostics and drug development applications, and higher R&D spending influence market growth. Applications for DNA sequencing can be found in forensics, personalized medicine, biomarkers, reproductive health, and other fields. DNA sequencing technology has enormous potential in clinical research and development for cancer diagnostics and therapies. The ability of NGS, or next-generation sequencing, to find and characterize clinically relevant genetic variations across several genes in a single test has recently been established quickly and affordably.
In June 2024: Roche announced a strategic partnership with a leading bioinformatics company to enhance DNA sequencing data analysis capabilities.
In November 2023, Illumina, Inc. unveiled its Global Health Access Initiative to improve the access to sequencing tools used in public health by poor nations. PacBio has entered into an agreement to acquire Apton Biosystems by August 2023. The takeover is expected to fasten short-read sequencer development, prompting the market growth
DNA Sequencing Market Segment Insights
DNA Sequencing Product Insights
Based on Product, the market segments of DNA Sequencing includes Consumables, Instruments, and Service. The consumable segment held the majority share in 2022, contributing most of the DNA Sequencing market revenue. The wide availability of reagents and kits for all library construction steps, such as DNA fragmentation, enrichment, adapter ligation, amplification, and quality control, contributes to a larger share of this segment. Most of these tools feature streamlined and simplified workflows, ready-to-use components, and compatibility with low-input and formalin-fixed specimens. The continuous availability and availability of reagents and kits have made WGS more accessible and affordable, driving the market of DNA sequencing.
DNA Sequencing Application Insights
Application has bifurcated the DNA Sequencing market data into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, and forensics. Biomarkers & cancer have a considerable share of the market. The market is expected to grow over the forecast year owing to the increasing prevalence of cancer and advancements in next-generation sequencing technologies. However, the personalized medicine segment is expected to witness considerable growth in the next-generation sequencing market over the forecast period owing to surging demand for drug treatments, advancements in research and development in healthcare, and rising awareness of NGS testing in the pharmaceutical and biotechnology industries.
DNA Sequencing Technology Insights
The DNA Sequencing market segmentation has been divided based on Technology into Semiconductor Sequencing, Sequencing by Ligation, and Pyrosequencing. Sequencing by ligation accounted for the largest market share of the DNA Sequencing due to the widespread use of DNA sequencing platforms in sequencing scenarios. It is likely to continue to dominate throughout the forecast period.
DNA Sequencing End-User Insights
Based on End-User, the DNA Sequencing industry has been segmented into academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics. The academic & government research institute segment is expected to contribute a higher market share due to the wide acceptance of Sanger techniques and NGS in academic and institutional research projects. Moreover, rising funding and investment plans increase these entities' demand for DNA sequencing products, leading to a more significant revenue share.
Figure 1 DNA Sequencing Market by End-User, 2022 & 2030 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
News: The most current findings come from the prospective research GEMINI, or Genomic Medicine in Ill Infants and Newborns, in which four hundred hospitalized newborns had their complete genomes sequenced and underwent targeted gene panel testing. Even though it took longer, whole-genome sequencing beat the targeted test at identifying the origin of an infant's symptoms, with a diagnosis rate of 49% as opposed to 27% for the smaller panel. One-fifth of the individuals saw modifications to their treatment, such as medical professionals choosing to use or forgo specific medications and surgical treatments.
DNA Sequencing Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. North American DNA Sequencing market, which accounted for USD 1.05 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Continuous technological development by major players, high investment in R&D, and availability of technologically advanced healthcare infrastructure have led North America to hold a leading market share in the DNA sequencing. Several government initiatives in the United States and Canada support drug development and cancer treatment research.
Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 DNA SEQUENCING MARKET SHARE BY REGION 2023 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's DNA Sequencing market accounts for the second-largest market share. Increasing adoption of organic growth strategies, such as product launches by key players in the Region to expand product portfolios, is expected to drive market growth over the forecast period. For example, in December 2021, Swiss-based pharmaceutical company F. Hoffmann-La Roche Ltd announced the launch of the AVENIO Edge System to provide a fully automated, integrated sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that provides integrated end-to-end control and reliable, consistently high-quality results. Further, the German market of DNA Sequencing held the largest market share, and the U.K. market of DNA Sequencing was the fastest-growing market in the European Region.
The Asia-Pacific DNA Sequencing Market is expected to grow at the fastest CAGR from 2024 to 2032. A growing customer base drives international companies to expand their business through strategic moves. A prominent California company has raised over $75 million to expand its desktop DNA sequencers to support the ongoing crisis of COVID-19. Moreover, the China market of DNA Sequencing held the largest market share, and the Indian market of DNA Sequencing was the fastest-growing market in the Asia-Pacific region.
DNA Sequencing Key Market Players & Competitive Insights
Major market players are spending a lot on R&D to increase their product lines, which will help the market of DNA Sequencing grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the DNA Sequencing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the DNA Sequencing industry to benefit clients and expand the market sector. The DNA Sequencing industry has provided medicine with some of the most significant benefits in recent years. In the market of DNA Sequencing, major players such as Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Cardiva Medical Inc., Morris Innovative Inc., and others are working on expanding the market demand by investing in research and development activities.
Illumina, Inc. is an American biotechnology company headquartered in San Diego, California, serving over 140 countries. Illumina was founded on April 1, 1998, to develop, manufacture, and sell integrated systems to analyze genetic variation and biological function. The company offers a range of products and services for sequencing, genotyping, gene expression, and proteomics. On January 9, 2023, pharmaceutical company Illumina Inc. and Nashville Biosciences LLC, a wholly owned Vanderbilt University Medical Center (VUMC) subsidiary, announced an agreement with biopharmaceutical company Amgen to sequence the whole genome of DNA samples of approximately 35,000 samples. The protocol helps accelerate therapeutic development through genomics and builds superior clinical genomic datasets.
Also, F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company with two divisions Pharmaceuticals and Diagnostics. The shares of its holding company, Roche Holding AG, are listed on the six major Swiss exchanges. The company is headquartered in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the world's leading provider of cancer treatments. In May 2020, F. Hoffman-La Roche Ltd. announced the acquisition of Stratos Genomics to advance the development of Roche nanopore sequencers. Roche believes the acquisition helps address clinical research needs and, thus, patient needs.
Key Companies in the DNA Sequencing market include
- Thermo Fisher Scientific Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
DNA Sequencing Industry Developments
Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology (February 2025)
Illumina announced new solutions in genomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics software. Key innovations include "Constellation mapped reads" for rare disease detection, a 5-base solution for methylation analysis and variant calling, and new spatial transcriptomics technology.
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery (March 2025)
The Alliance for Genomic Discovery, launched by Illumina and NashBio, has completed sequencing 250,000 whole genomes, significantly accelerating drug discovery efforts. This large-scale clinical genomic resource will provide a dynamic research platform.
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 (April 2025)
QIAGEN launched new QIAseq panels for comprehensive genomic profiling (CGP) in cancer research and clinical applications, covering over 700 genes. They also announced updates to partnerships with Element Biosciences and Myriad Genetics to integrate these panels and develop new assays.
GENEWIZ (from Azenta Life Sciences): While GENEWIZ's website highlights its DNA sequencing services (Sanger, Whole Genome Sequencing, etc.), there isn't prominent news within the last 6 months specifically about new DNA sequencing technologies or major breakthroughs from their newsroom. Their latest news seems to be more general updates on software or internal processes.
In August 2023, PacBio announced a research collaboration with the University of Washington aimed at studying the ability of HiFi long-read WGS. This move is likely to increase analysis rates in persons with various genetic conditions.
In June 2023, Illumina, Inc. launched PrimateAI-3D, which is an Artificial Intelligence (AI) software that can accurately predict disease-causing genetic mutations in people, thus increasing demand for products such as this one that are used to understand genetic makeup.
In August 2023, GeneDx and PacBio announced on a research collaboration alongside the University of Washington aimed at understanding Long-read Whole Genome Sequencing for Better Diagnostic Yield in Neonatal Care. This segment is anticipated to be driven by such initiatives.For instance, Complete Genomics, Inc., a US firm, won “The Oscars of Innovation” award from R&D World Magazine for its ultra-high throughput gene sequencer DNBSEQ-T20×2*("T20"). Therefore it will lead to fresh developments within regional markets due to these recognitions/awards received on innovative products.
In March 2023 saw the unveiling of Illumina Inc.’s Connected Insights cloud-based software meant for supporting tertiary analysis of clinical NGS data. Thus, the market growth rate will improve over time because of these moves.One example would be the establishment of a WGS facility at All India Institute of Medical Sciences (AIIMS) Nagpur, along with JHPIEGO-USAID-RISE.In fact, we should go further and say that All India Institute of Medical Sciences (AIIMS) Nagpur, together with JHPIEGO-USAID-RISE, announced in July 2022 that it is setting up a WGS facility.
In June 2022 saw the partnership between Ultima Genomics and Nvidia for leveraging artificial intelligence (AI) across multiple stages of DNA sequencing and analysis. In addition, Ultima's instrument uses Nvidia Clara AI computing platform with Nvidia A30 GPUs which provide highly accurate secondary and primary analysis to customers who need genomic analyses at scale. This would bring innovation across the industry through the adoption of AI and cloud computing. QIAGEN revealed its partnership with Helix to develop the NGS companion diagnostics for various hereditary diseases by January 2023. For example, PacBio introduced a new software pipeline for human whole genome sequencing data analysis as one of the major players in October 2023. Accordingly, an increase in launches of analysis and computational software will support segment growth during the forecast period. October 2022 PacBio announced the launch of two genome sequencing systems, the Revio long-read sequencing system, and the Onso short-read sequencing system. Deep learning methods have also been integrated into Revio to detect DNA methylation from routinely sequenced libraries. March 2022 Element Biosciences revealed technical details of its long-awaited Aviti DNA sequencer. The new benchtop instrument uses sequencing-by-synthesis chemistry, which Element says reduces reagent usage, costing about $7 per gigabyte.
DNA Sequencing Market Segmentation
DNA Sequencing Product Outlook
DNA Sequencing Application Outlook
DNA Sequencing Technology Outlook
DNA Sequencing End-User Outlook
- Academic & Government Research Institutes
DNA Sequencing Regional Outlook
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 13.46 billion |
| Market Size 2024 |
USD 15.63billion |
| Market Size 2032 |
USD 46.85 billion |
| Compound Annual Growth Rate (CAGR) |
12.97% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product, Application, Technology, End-User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies Ltd., Macrogen Inc., Perkin Elmer Inc., Pacific Biosciences of California Inc., BGI. |
| Key Market Opportunities |
New product launches and R&D Amongst major key Players. |
| Key Market Dynamics |
Growing requirement of breeders for animals and plant production Development in technology It is increasing research and development. |
Frequently Asked Questions (FAQ) :
The DNA sequencing market size was valued at USD 13.46 Billion in 2023.
The market is projected to grow at a CAGR of 12.97% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, and F. Hoffmann-La Roche Ltd.
The consumable DNA sequencing category dominated the market in 2023.
Biomarkers & cancer had the largest share of the market.
